Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Life trajectories, genetic testing, and risk reduction decisions in 18-39 year old women at risk for hereditary breast and ovarian cancer.

Hamilton R, Williams JK, Bowers BJ, Calzone K.

J Genet Couns. 2009 Apr;18(2):147-59. doi: 10.1007/s10897-008-9200-1. Epub 2008 Nov 1.

2.

'Cancer doesn't have an age': genetic testing and cancer risk management in BRCA1/2 mutation-positive women aged 18-24.

Werner-Lin A, Hoskins LM, Doyle MH, Greene MH.

Health (London). 2012 Nov;16(6):636-54. doi: 10.1177/1363459312442420. Epub 2012 Apr 30.

PMID:
22547552
3.

Maximising survival: the main concern of women with hereditary breast and ovarian cancer who undergo genetic testing for BRCA1/2.

Jeffers L, Morrison PJ, McCaughan E, Fitzsimons D.

Eur J Oncol Nurs. 2014 Aug;18(4):411-8. doi: 10.1016/j.ejon.2014.03.007. Epub 2014 Apr 13.

PMID:
24731853
4.

Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting.

Morgan D, Sylvester H, Lucas FL, Miesfeldt S.

Fam Cancer. 2009;8(4):277-87. doi: 10.1007/s10689-009-9242-z. Epub 2009 Apr 4.

PMID:
19347608
5.

Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.

Fourati A, Louchez MM, Fournier J, Gamoudi A, Rahal K, El May MV, El May A, Revillion F, Peyrat JP.

Bull Cancer. 2014 Nov;101(11):E36-40. doi: 10.1684/bdc.2014.2049.

PMID:
25418591
6.

Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.

Schwartz MD, Isaacs C, Graves KD, Poggi E, Peshkin BN, Gell C, Finch C, Kelly S, Taylor KL, Perley L.

Cancer. 2012 Jan 15;118(2):510-7. doi: 10.1002/cncr.26294. Epub 2011 Jun 29.

7.

Identifying and managing hereditary risk of breast and ovarian cancer.

Frank TS, Critchfield GC.

Clin Perinatol. 2001 Jun;28(2):395-406. Review.

PMID:
11499060
8.

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van t'veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR.

JAMA. 2010 Sep 1;304(9):967-75. doi: 10.1001/jama.2010.1237.

9.

Being young, female, and BRCA positive.

Hamilton R.

Am J Nurs. 2012 Oct;112(10):26-31, quiz 46, 32.

PMID:
22982855
10.

Decision-making on preimplantation genetic diagnosis and prenatal diagnosis: a challenge for couples with hereditary breast and ovarian cancer.

Derks-Smeets IA, Gietel-Habets JJ, Tibben A, Tjan-Heijnen VC, Meijer-Hoogeveen M, Geraedts JP, van Golde R, Gomez-Garcia E, van den Bogaart E, van Hooijdonk M, de Die-Smulders CE, van Osch LA.

Hum Reprod. 2014 May;29(5):1103-12. doi: 10.1093/humrep/deu034. Epub 2014 Mar 6.

PMID:
24603131
11.

Attitudes and distress levels in women at risk to carry a BRCA1/BRCA2 gene mutation who decline genetic testing.

Lodder L, Frets PG, Trijsburg RW, Klijn JG, Seynaeve C, Tilanus MM, Bartels CC, Meijers-Heijboer EJ, Verhoog LC, Niermeijer MF.

Am J Med Genet A. 2003 Jun 15;119A(3):266-72.

PMID:
12784290
12.

Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.

Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, Cobleigh M, Esserman L, Lindor NM, Neuhausen SL, Olopade OI.

JAMA. 2005 Oct 19;294(15):1925-33.

PMID:
16234499
13.
14.

Differences between women who pursued genetic testing for hereditary breast and ovarian cancer and their at-risk relatives who did not.

Katapodi MC, Northouse L, Pierce P, Milliron KJ, Liu G, Merajver SD.

Oncol Nurs Forum. 2011 Sep;38(5):572-81. doi: 10.1188/11.ONF.572-581.

PMID:
21875844
15.
16.

Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization.

Levy DE, Garber JE, Shields AE.

J Gen Intern Med. 2009 Jul;24(7):822-8. doi: 10.1007/s11606-009-1009-6. Epub 2009 May 20.

17.

Breast cancer and ovarian cancer genetics.

Edlich RF, Winters KL, Lin KY.

J Long Term Eff Med Implants. 2005;15(5):533-45. Review.

PMID:
16218901
18.

A multi-case report of the pathways to and through genetic testing and cancer risk management for BRCA mutation-positive women aged 18-25.

Hoskins LM, Werner-Lin A.

J Genet Couns. 2013 Feb;22(1):27-38. doi: 10.1007/s10897-012-9521-y. Epub 2012 Aug 3.

19.

Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer.

Armstrong K, Micco E, Carney A, Stopfer J, Putt M.

JAMA. 2005 Apr 13;293(14):1729-36.

PMID:
15827311
20.

Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.

Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, Beeri R, Gal M, Grinshpun-Cohen J, Djemal K, Mandell JB, Lee MK, Beller U, Catane R, King MC, Levy-Lahad E.

Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14205-10. doi: 10.1073/pnas.1415979111. Epub 2014 Sep 5.

Supplemental Content

Support Center